Riskpilot← Back to searchSign inGet full accessLumexia AB
ABActiveOrg 5567554992Fahnehielmsvägen 15General medical practice activities · NACE 8621Est. 20080 employees
Revenue 2025
SEK 804K
EBITDA margin
88.7%
+6030% vs 2024
Equity ratio
67.3%
Financial strength
Net profit 2025
SEK 591K
+5018% vs 2024
| Revenue | SEK 804K | — |
| EBITDA | SEK 713K | +6030% |
| Net profit | SEK 591K | +5018% |
| Total assets | SEK 1M | +995% |
| Equity | SEK 676K | +698% |
| Employees | 0 | — |
Legal name
Lumexia AB
Org number
5567554992
Legal form
Aktiebolag
NACE code
8621 · General medical practice activities
Founded
8 april 2008
Share capital
SEK 100 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2025-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen
Company purpose
Aktiebolaget ska bedriva konsultation inom vård och omsorg.
Address
Fahnehielmsvägen 15
Phone
+46706175959
Email
majid.sarisarraf@gmail.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 804 |
| Staff expenses | — | — | — | −0 | −2 |
| EBITDA | −7 | −12 | −11 | −12 | 713 |
| Depreciation & amort. | −11 | −11 | −9 | — | — |
| EBIT | −18 | −23 | −20 | −12 | 713 |
| Net financials | — | — | — | −0 | — |
| Profit before tax | −18 | −23 | −20 | −12 | 713 |
| Tax | −0 | −0 | −0 | — | −122 |
| Net profit | −18 | −23 | −20 | −12 | 591 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 146 | 124 | 104 | 92 | 1 005 |
| Equity | 140 | 117 | 97 | 85 | 676 |
| Long-term debt | 0 | 0 | 0 | — | — |
| Short-term debt | 6 | 7 | 7 | 7 | 328 |
| Total debt | 6 | 7 | 7 | 7 | 328 |
EBITDA margin
88.7%
This company
15.8%
Market median
+461% vs market
20212025
Equity ratio
67.3%
This company
38.2%
Market median
+76% vs market
20212025
Return on equity
87.5%
This company
18.4%
Market median
+376% vs market
20212025
Net profit margin
73.6%
This company
8.1%
Market median
+809% vs market
20212025
Asset turnover
0.80×
This company
1.12×
Market median
-29% vs market
20212025
Debt / equity
0.49×
This company
0.62×
Market median
+21% vs market
20212025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2025-01-01 – 2025-12-31
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
MS Chief Executive Officer | Chief Executive Officer | 2021 |
| Former (1) | ||
MK Chief Executive Officer | Chief Executive Officer | 2020 – 2021 |
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
| Deputy Board Member | 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Lumexia AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Majid Sari-Sarraf | Chief Executive Officer | 0 companies |
| Madeleine Kristine Carlsson | Chief Executive Officer | 0 companies |
| Filip Reza Sari-Sarraf | Deputy Board Member | 0 companies |